Liu Airong, Gu Qiuling, Wang Mingjing
Hong Kong Middle Road Clinic, Integrated Chinese and Western Medicine Hospital of Qingdao (The 5th People's Hospital of Qingdao), Qingdao, Shandong 266073, P.R. China.
Exp Ther Med. 2020 Oct;20(4):3687-3694. doi: 10.3892/etm.2020.9126. Epub 2020 Aug 19.
The present study aimed to investigate the effects of levetiracetam tablets and lacosamide (LCM) on therapeutic efficacy and neural function in patients with epilepsy. We assigned 252 patients with refractory partial seizures admitted to our hospital to receive either levetiracetam tablets [120 patients, the control group (CG)] or levetiracetam tablets combined with LCM [132 patients, the joint group (JG)]. The bone mineral density and neural function between the two groups at 6 months before and after treatment were compared. The total response rate was higher in the JG than in the CG (P<0.05). There was no significant difference in the comparison of the multiple indexes between the two groups before treatment (P>0.05). The frequency of seizures was reduced after treatment in the two groups, however, it was lower in the JG compared with the CG (P<0.05). The levels of neurological indicators were significantly reduced after treatment in the two groups (P<0.05), however, the reduction was more marked in the JG than in the CG. The bone mineral density (BMD) of the femoral neck decreased after treatment in the two groups (P<0.05), but there was no difference between the two groups after treatment (P>0.05). The calcium content decreased after treatment in the two groups (P<0.05), but there was no difference between the two groups after treatment (P>0.05). The comparison of other bone metabolism markers between the two groups exhibited no significant differences. The combination therapy greatly increased the quality of life score and the 1-year drug retention rate. To sum up, levetiracetam tablets combined with LCM significantly enhanced the therapeutic effect and improved the neural function in patients with refractory partial seizures, however this therapy may cause a slight adverse effect on BMD and bone metabolism in the short term.
本研究旨在探讨左乙拉西坦片和拉科酰胺（LCM）对癫痫患者治疗效果及神经功能的影响。我们将我院收治的252例难治性部分性癫痫患者分为两组，分别给予左乙拉西坦片治疗（120例，对照组）或左乙拉西坦片联合LCM治疗（132例，联合组）。比较两组治疗前后6个月的骨密度和神经功能。联合组的总有效率高于对照组（P<0.05）。两组治疗前多项指标比较差异无统计学意义（P>0.05）。两组治疗后癫痫发作频率均降低，但联合组低于对照组（P<0.05）。两组治疗后神经学指标水平均显著降低（P<0.05），但联合组降低更明显。两组治疗后股骨颈骨密度（BMD）均降低（P<0.05），但治疗后两组间差异无统计学意义（P>0.05）。两组治疗后钙含量均降低（P<0.05），但治疗后两组间差异无统计学意义（P>0.05）。两组其他骨代谢标志物比较差异无统计学意义。联合治疗显著提高了生活质量评分和1年药物保留率。综上所述，左乙拉西坦片联合LCM显著增强了难治性部分性癫痫患者的治疗效果并改善了神经功能，但该治疗可能在短期内对骨密度和骨代谢产生轻微不良影响。
